Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - virus vcp1338 - immunostimulants, zdravila z delovanjem na novotvorbe in imunomodulatorji agenti, immunostimulants, - mačke - immunotherapy, da se uporablja v povezavi z kirurgijo in radioterapijo pri mačkah z fibrosarcoma (2-5 cm premer) brez metastaze ali limfnih vozlišč vključenost, zmanjšanje tveganja za ponovitev bolezni in poveča čas do ponovitve (lokalne ponovitve ali metastaze).

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - imepitoin - drugi antiepileptics, antiepileptics - psi - za zmanjšanje pogostnosti splošnih napadov zaradi idiopatske epilepsije pri psih za uporabo po skrbni oceni alternativnih možnosti zdravljenja.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - firokoksib - anti-inflammatory and anti-rheumatic products, non-steroids - psi - tabletsfor za lajšanje bolečin in vnetja, povezana z osteoartrozo v psi. za lajšanje pooperativne bolečine in vnetja, povezanih z mehkimi tkivi, ortopedskimi in zobozdravstvenimi posegi pri psih. ustni pastealleviation bolečine in vnetja, povezana z osteoartritisom in zmanjšanje s tem povezanega lameness pri konjih.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - west nile rekombinantne canarypox virus (vcp2017 virus) - immunologicals za kopitarjev, konj, immunologicals - konji - aktivna imunizacija konj od petih mesecev starosti proti bolezni west west nile z zmanjšanjem števila viremskih konjev. Če so prisotni klinični znaki, se njihovo trajanje in resnost zmanjšata.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - insulin human - insulins in analogov za injiciranje, vmesne-deluje - cats; dogs - za zdravljenje sladkorne bolezni pri mačkah in psih doseči zmanjšanje hyperglycaemia in izboljšanje povezane klinične znake.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - mačji levkemijo virus rekombinantne canarypox virus (vcp97) - immunologicals za skupin felidae, - mačke - aktivna imunizacija mačk, starih 8 tednov ali več, proti mačji levkemiji za preprečevanje vztrajne viremije in kliničnih znakov s tem povezane bolezni. začetek imunosti je bil dokazan 2 tedna po osnovnem cepljenju. trajanje imunitete je eno leto po zadnjem cepljenju.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - virus vcp65 - imunologija - mačke - aktivna imunizacija mačk, starih 12 tednov ali več, za preprečevanje smrtnosti zaradi okužbe z steklino. začetek imunosti: 4 tedne po osnovnem cepljenju. trajanje imunitete po primarnem cepljenju: 1 leto. trajanje imunosti po ponovnem cepljenju: 3 leta.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Eiropas Savienība - slovēņu - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.